This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
This report comes with 10% free customization, enabling you to add data that meets your specific business needs.
The factors such as increasing urban population, growing ageing population, rising female workforce, escalating personal disposable income, evolving personal healthcare expenditure and a growing number of plastic surgery and dermatology clinics are expected to drive the market growth. However, the growth of the industry would be challenged by stringent regulations, patient health-associated risk and limited access to patent rights. A few notable trends include accelerating pharmaceutical R&D spending, progressing botulinum toxin products pipeline, rising minimally invasive procedures and growing preference for combination therapy.
Presently, botulinum toxin and HA dermal fillers are widely used in therapeutics and aesthetics procedures for various purposes. The demand for these products was higher in the therapeutic sector due to increasing approval of these injectables to manage nerve and muscular spasticity disorders by medicinal authorities.
The fastest-growing regional market is North America owing to the increasing geriatric population and rising demand for non-invasive aesthetic procedures in the US and Canada. The US is the largest market of botulinum toxin and HA dermal fillers and is already well-penetrated at developed market levels.
Scope of the report:
- The report provides a comprehensive analysis of the global botulinum toxin and HA dermal filler market, segmented on the basis of applications i.e. therapeutics and aesthetics.
- The major regional markets (North America, Europe, and Asia-Pacific) have been analysed, along with country coverage of the U.S, Germany, Japan, Korea, and China.
- The market dynamics such as growth drivers, market trends and challenges are analysed in-depth.
- The competitive landscape of the market, along with the company profiles of leading players (Allergan, Ipsen, Merz Pharma, Daewoong Pharmaceuticals, Medytox and Shanghai Haohai) are also presented in detail.
Key Target Audience:
- Botulinum Toxin and HA Dermal Filler Manufacturers
- Raw Material/Component Suppliers
- End Users (Hospitals & Clinics)
- Consulting Firms
- Investment Banks
- Government Bodies & Regulating Authorities
- Allergan Plc
- Daewoong Pharmaceuticals Co.
- Ipsen S.A.
- Medytox Inc.
- Merz Pharma GmbH & Co. KGaA
- Shanghai Haohai Biological Technology Co. Ltd
